This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The basis of the analysis of the effectiveness study was treatment completers only. The main outcome measures were abstinence from both alcohol and drugs, which were measured using the abbreviated form of the addiction severity questionnaire. The groups were shown to be comparable in terms of their baseline characteristics, medical status, treatment initiation status, and length of stay by treatment condition. Within the sample, only 1 of the 28 characteristics (family or social problem severity) was found to be statistically different. All analyses were replicated, controlling for baseline variables on which the nonresponders differed.
Effectiveness results
Both groups showed improvement on all drug and alcohol measures.
Overall, there was no difference in the total 30-day abstinence rates between the integrated care (68%) and independent care (63%) groups, (p=0.18). There were also no differences in the alcohol abstinence rates (77% versus 71%, p=0.07) and other drug abstinence (81% versus 80%, p=0.41).
For the sub-population of patients without SAMCs, there was also no difference in the total 30-day abstinence rates (between the integrated care (66%) and independent care (73%) group, (p=0.23). Neither were there any differences in the alcohol abstinence rates (73% versus 78%, p=0.41) and other drug abstinence rates (84% versus 87%, p=0.50).
For the sub-population of patients with SAMCs, there were significant differences in the total 30-day abstinence rates for the integrated care (69%) and independent care (55%) groups, (p=0.006), and for alcohol abstinence (80% versus 65%, p=0.002). However, there was no statistical difference for drug abstinence (81% versus 74%, p=0.11).
Clinical conclusions
Integrated medical and substance abuse treatment has been found to be effective for individuals suffering with SAMCs.
Measure of benefits used in the economic analysis
The summary measure of benefit used in the economic analysis was person abstinence. This was derived directly from the effectiveness results obtained.
Direct costs
The unit costs of services were determined through activity-based costing. The direct costs were allocated in proportion to the provider time spent on activities such as individual and group therapy. The costs of visits outside the CDRP were obtained from Kaiser's cost management information system. The unit costs were derived by allocating the actual CDRP expenses to weighted activity volumes, which were provided by the department. The cost per encounter data were obtained by applying the unit costs of services to their actual use. The overhead costs were allocated in proportion to the direct costs, and were allocated to the unit costs via step-down accounting methods. The costs were treated stochastically, using t-tests to compare differences in CDRP treatment and medical costs by treatment group. In addition, the treatment costs were predicted from an ordinary least-squares regression of treatment costs on the same set of predictors used in the outcome model.
Statistical analysis of costs

Indirect Costs
The indirect costs were not included in the analysis.
Currency
US dollars ($).
Sensitivity analysis
Uncertainties inherent in the incremental cost-effectiveness ratio (ICER) were addressed using 1-way and 2-way sensitivity analysis techniques. This was supplemented by using the bootstrap method to obtain the empirical sampling distribution of the ICER.
Estimated benefits used in the economic analysis
Following logistic regression controlling for baseline severity, integrated care was slightly, but not significantly, associated with total abstinence (odds ratio, OR=1.28; 95% confidence interval, CI: 0.91 --1.80, p=0.16). In addition, patients with SAMCs in the integrated model group were more likely to achieve total abstinence (OR 1.90, 95% CI: 1.22 -2.97) and alcohol abstinence (OR 2.22, 95% CI: 1.35 -3.64) relative to patients with SAMCs in the independent model.
Cost results
The 
Synthesis of costs and benefits
A synthesis was only performed for the SAMC sub-population.
For the SAMC sub-group, the ICER was $1,581 per additional person abstinent in the integrated services relative to the independent services.
